Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.665
-0.010 (-1.50%)
At close: Nov 20, 2024, 4:00 PM
0.698
+0.033 (4.99%)
After-hours: Nov 20, 2024, 7:37 PM EST
Adaptimmune Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 175.04 | 60.28 | 27.15 | 6.15 | 3.96 | 1.12 | Upgrade
|
| Revenue Growth (YoY) | 146.27% | 122.05% | 341.50% | 55.36% | 252.76% | -98.11% | Upgrade
|
| Cost of Revenue | 71 | 126.51 | 127.73 | 111.09 | 91.57 | 97.5 | Upgrade
|
| Gross Profit | 104.05 | -66.23 | -100.58 | -104.94 | -87.61 | -96.38 | Upgrade
|
| Selling, General & Admin | 84.14 | 71.81 | 61.09 | 57.31 | 45.8 | 43.39 | Upgrade
|
| Research & Development | 72.17 | - | - | - | - | - | Upgrade
|
| Operating Expenses | 156.31 | 71.81 | 61.09 | 57.31 | 45.8 | 43.39 | Upgrade
|
| Operating Income | -52.26 | -138.04 | -161.67 | -162.25 | -133.41 | -139.77 | Upgrade
|
| Interest & Investment Income | 6.41 | 5.96 | 1.54 | 1.1 | 2.31 | 2.77 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.31 | -0.81 | -0.54 | 3.85 | 1.11 | -0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.86 | -0.2 | - | -0.01 | -0.03 | 0.2 | Upgrade
|
| EBT Excluding Unusual Items | -50.65 | -133.08 | -160.66 | -157.31 | -130.02 | -136.94 | Upgrade
|
| Merger & Restructuring Charges | 7.17 | -1.7 | -2.3 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.2 | 0.2 | - | 0.01 | 0.09 | 0.01 | Upgrade
|
| Other Unusual Items | - | 22.05 | - | - | - | - | Upgrade
|
| Pretax Income | -43.29 | -112.54 | -162.96 | -157.3 | -129.93 | -136.92 | Upgrade
|
| Income Tax Expense | 1.23 | 1.34 | 2.5 | 0.79 | 0.16 | 0.24 | Upgrade
|
| Net Income | -44.52 | -113.87 | -165.46 | -158.09 | -130.09 | -137.17 | Upgrade
|
| Net Income to Common | -44.52 | -113.87 | -165.46 | -158.09 | -130.09 | -137.17 | Upgrade
|
| Shares Outstanding (Basic) | 245 | 201 | 161 | 156 | 142 | 105 | Upgrade
|
| Shares Outstanding (Diluted) | 245 | 201 | 161 | 156 | 142 | 105 | Upgrade
|
| Shares Change (YoY) | 32.51% | 24.73% | 3.47% | 9.36% | 35.72% | 7.78% | Upgrade
|
| EPS (Basic) | -0.18 | -0.57 | -1.03 | -1.01 | -0.91 | -1.31 | Upgrade
|
| EPS (Diluted) | -0.18 | -0.57 | -1.03 | -1.02 | -0.91 | -1.31 | Upgrade
|
| Free Cash Flow | -55.17 | -145.56 | -171.27 | 2.16 | -55.93 | -114.1 | Upgrade
|
| Free Cash Flow Per Share | -0.22 | -0.72 | -1.06 | 0.01 | -0.39 | -1.09 | Upgrade
|
| Gross Margin | 59.44% | -109.87% | - | - | - | - | Upgrade
|
| Operating Margin | -29.86% | -228.99% | -595.51% | -2638.58% | -3370.52% | -12457.22% | Upgrade
|
| Profit Margin | -25.43% | -188.90% | -609.46% | -2570.99% | -3286.81% | -12225.04% | Upgrade
|
| Free Cash Flow Margin | -31.52% | -241.47% | -630.86% | 35.05% | -1413.14% | -10169.25% | Upgrade
|
| EBITDA | -41 | -128.2 | -155.59 | -155.68 | -125.81 | -131.76 | Upgrade
|
| EBITDA Margin | -23.42% | -212.67% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 11.26 | 9.84 | 6.08 | 6.57 | 7.59 | 8.01 | Upgrade
|
| EBIT | -52.26 | -138.04 | -161.67 | -162.25 | -133.41 | -139.77 | Upgrade
|
| EBIT Margin | -29.86% | -228.99% | - | - | - | - | Upgrade
|
| Revenue as Reported | 60.28 | 60.28 | 27.15 | 6.15 | 3.96 | 1.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.